Zepeda-Morales Katherine, Bravo David, Aránguiz-Barrera Jonathan, Ampuero Estibaliz, Renard Georgina M, Pelissier Teresa, Hernández Alejandro, Retamal Jeffri S, Constandil Luis
Laboratory of Neurobiology, Department of Biology, Faculty of Chemistry and Biology, University of Santiago de Chile, Santiago, Chile.
Laboratory of Neurobiology of Behavior, Department of Biology, Faculty of Chemistry and Biology, University of Santiago de Chile, Santiago, Chile.
Pain. 2025 Jun 1;166(6):1369-1381. doi: 10.1097/j.pain.0000000000003476. Epub 2024 Dec 3.
A well-recognized molecular entity involved in pain-related neuroplasticity is the N-methyl-D-aspartate receptor (NMDAR), which is crucial for developing chronic pain. Likewise, the pannexin 1 (Panx1) channel has been described as necessary for initiating and maintaining neuropathic pain, driving nociceptive signals dependent on spinal NMDAR through several possible mechanisms. Through behavioral, pharmacological, and molecular approaches, our study in male rats has revealed several key findings: (1) neurons located in spinal cord laminae I and II express functional Panx1 channels in both neuropathic and sham rats. These channels can open (indicated by YOPRO-1 uptake) through the stimulation of NMDARs with intrathecal NMDA; (2) intrathecal NMDA leads to increased expression of pSrc and pPanx1 in dorsal horn neurons. This elevation exacerbates existing mechanical hyperalgesia in nerve-injured rats; (3) inhibition of Src with intrathecal PP2 or blockade of Panx1 with intrathecal 10 Panx effectively mitigates NMDA-induced effects and reduces the spontaneous mechanical hyperalgesia of nerve-injured rats. Notably, while 10 Panx successfully alleviates hyperalgesia, it does not alter pSrc expression; and (4) NMDA-stimulated YOPRO-1 uptake in neurons of laminae I-II of spinal cord slices were prevented by the NMDAR antagonist D-AP5, the Src inhibitor PP2 (but not PP3), as well as with the 10 Panx and carbenoxolone. Therefore, NMDAR activation in dorsal horn neurons triggers an NMDAR-Src-Panx1 signaling pathway, where Panx1 acts as an enhancing effector in neuropathic pain. This implies that disrupting the NMDAR-Panx1 communication (eg, through Src inhibitors and/or Panx1 blockers) may offer a valuable strategy for managing some forms of chronic pain.
一种与疼痛相关的神经可塑性密切相关的分子实体是N-甲基-D-天冬氨酸受体(NMDAR),它对于慢性疼痛的形成至关重要。同样,泛连接蛋白1(Panx1)通道被认为是引发和维持神经性疼痛所必需的,它通过几种可能的机制驱动依赖于脊髓NMDAR的伤害性信号。通过行为学、药理学和分子生物学方法,我们对雄性大鼠的研究揭示了几个关键发现:(1)位于脊髓I层和II层的神经元在神经性疼痛大鼠和假手术大鼠中均表达功能性Panx1通道。这些通道可通过鞘内注射NMDA刺激NMDAR而开放(由YOPRO-1摄取表明);(2)鞘内注射NMDA导致背角神经元中pSrc和pPanx1表达增加。这种升高加剧了神经损伤大鼠现有的机械性痛觉过敏;(3)鞘内注射PP2抑制Src或鞘内注射10 Panx阻断Panx1可有效减轻NMDA诱导的效应,并降低神经损伤大鼠的自发性机械性痛觉过敏。值得注意的是,虽然10 Panx成功减轻了痛觉过敏,但它并未改变pSrc的表达;(4)NMDAR拮抗剂D-AP5、Src抑制剂PP2(而非PP3)以及10 Panx和羧苄青霉素可阻止脊髓切片I-II层神经元中NMDA刺激的YOPRO-1摄取。因此,背角神经元中的NMDAR激活触发了NMDAR-Src-Panx1信号通路,其中Panx1在神经性疼痛中起增强效应器的作用。这意味着破坏NMDAR-Panx1通讯(例如,通过Src抑制剂和/或Panx1阻滞剂)可能为管理某些形式的慢性疼痛提供一种有价值的策略。